Pelthos Therapeutics Inc. (PTHS) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Pelthos Therapeutics Inc. (PTHS) Healthcare & Pipeline Overview

Pelthos Therapeutics Inc. is a bio-pharmaceutical company specializing in developing and commercializing therapies for unmet medical needs, with a focus on dermatology. Their primary product, ZELSUVMI, targets molluscum contagiosum, leveraging their NITRICIL technology platform to address specific patient populations within the broader healthcare sector.

What Is the Investment Thesis for PTHS?

Pelthos Therapeutics Inc. presents a focused investment opportunity within the biopharmaceutical sector, primarily driven by the commercialization of ZELSUVMI for molluscum contagiosum. With a market capitalization of $78.0M, the company's valuation hinges on the successful penetration of ZELSUVMI into the dermatology market. A gross margin of 62.6% indicates potential profitability as sales scale. Key catalysts include expanding the market reach of ZELSUVMI and further development of the NITRICIL technology platform. However, the company's negative profit margin of -257.9% and a beta of 3.99 highlight significant financial risks and market volatility. The investment thesis depends on Pelthos's ability to effectively manage its operational costs and capitalize on its existing product and technology.

Based on FMP financials and quantitative analysis

PTHS Key Highlights

Market Cap of $78.0M reflects the company's current valuation in the biopharmaceutical market.

• Gross Margin of 62.6% indicates the potential for profitability as sales of ZELSUVMI increase.
• Profit Margin of -257.9% highlights the company's current financial challenges and need for improved operational efficiency.
• Beta of 3.99 suggests high volatility compared to the overall market.
• ZELSUVMI is approved for the treatment of molluscum contagiosum in adults and children 1 year of age and older, providing a focused revenue stream.

Who Are PTHS's Competitors?

PTHS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are PTHS's Key Strengths?

FDA-approved product (ZELSUVMI) for molluscum contagiosum.

• Proprietary NITRICIL technology platform.
• Focus on unmet medical needs in dermatology.
• Experienced management team.

What Are PTHS's Weaknesses?

Limited product portfolio with reliance on ZELSUVMI.

• Negative profit margin and high operational costs.
• Small market capitalization and limited financial resources.
• High beta indicating significant market volatility.

What Could Drive PTHS Stock Higher?

Expansion of ZELSUVMI's market reach through targeted marketing and sales efforts.

• Development of new NITRICIL-based therapies for additional dermatological indications.
• Potential strategic collaborations or partnerships with larger pharmaceutical companies.
• Regulatory milestones for new product candidates in the pipeline.

What Are the Key Risks for PTHS?

Financial-distress signal — its Altman Z-Score of -1.84 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Competition from established pharmaceutical companies and generic alternatives.
• Regulatory challenges and delays in product approvals.
• Market volatility and economic downturns affecting investor sentiment.
• Product liability claims and litigation risks.
• Dependence on the success of ZELSUVMI and the NITRICIL technology platform.

What Are the Growth Opportunities for PTHS?

• Expansion of ZELSUVMI's Market Reach: Pelthos can pursue growth by expanding the market reach of ZELSUVMI through strategic partnerships, targeted marketing campaigns, and geographic expansion. The global market for molluscum contagiosum treatment is estimated to grow, offering substantial opportunities for increased sales and market share. Timeline: Ongoing, with continuous efforts to penetrate new markets and patient segments.
• Development of New NITRICIL-Based Therapies: Pelthos can leverage its proprietary NITRICIL technology platform to develop new therapies for other dermatological conditions or indications beyond molluscum contagiosum. This diversification strategy can broaden the company's product portfolio and revenue streams. Timeline: Ongoing research and development efforts with potential product launches in the next 3-5 years.
• Strategic Collaborations and Partnerships: Pelthos can pursue strategic collaborations with larger pharmaceutical companies or research institutions to accelerate the development and commercialization of its products. Partnerships can provide access to additional resources, expertise, and market channels. Timeline: Ongoing, with potential partnership agreements within the next 1-2 years.
• Acquisition of Complementary Technologies or Products: Pelthos can explore opportunities to acquire complementary technologies or products that align with its strategic focus and enhance its product portfolio. Acquisitions can provide access to new markets, technologies, and revenue streams. Timeline: Opportunistic, with potential acquisitions based on market conditions and available opportunities.
• Geographic Expansion into International Markets: Pelthos can expand its operations into international markets, particularly in regions with a high prevalence of molluscum contagiosum or unmet medical needs in dermatology. International expansion can significantly increase the company's revenue potential and market presence. Timeline: Potential expansion into select international markets within the next 3-5 years.

What Are PTHS's Competitive Advantages?

• Proprietary NITRICIL technology platform provides a competitive advantage in developing novel therapies.
• ZELSUVMI is an FDA-approved product for the treatment of molluscum contagiosum, offering a differentiated solution.
• Strong focus on dermatology and unmet medical needs allows for targeted product development and commercialization.
• Established relationships with dermatologists and healthcare providers facilitate market access and adoption.

What Does PTHS Do?

Pelthos Therapeutics Inc., formerly known as Channel Therapeutics Corporation, is a biopharmaceutical company founded in 2002 and headquartered in Durham, North Carolina. The company is dedicated to the development and commercialization of therapeutic products designed to address unmet treatment burdens in various patient populations. Pelthos's current portfolio is highlighted by ZELSUVMI, a topical treatment approved for molluscum contagiosum in adults and children aged one year and older. This product represents a significant advancement in addressing this common dermatological condition. In addition to ZELSUVMI, Pelthos Therapeutics leverages its proprietary NITRICIL technology platform, which utilizes nitric oxide-based formulations to create innovative therapeutic solutions. The company's strategic focus is on identifying and developing therapies that offer improved efficacy, safety, and patient convenience compared to existing treatment options. Pelthos Therapeutics operates within the highly competitive biotechnology sector, striving to establish a strong market presence through targeted product development and commercialization efforts.

What Products and Services Does PTHS Offer?

• Develop and commercialize therapeutic products.
• Focus on unmet treatment burdens in patients.
• Offer ZELSUVMI for the treatment of molluscum contagiosum.
• Provide NITRICIL, a proprietary nitric oxide-based technology platform.
• Research and develop new therapies for dermatological conditions.
• Seek strategic partnerships for product development and commercialization.

How Does PTHS Make Money?

• Develop and commercialize pharmaceutical products, primarily focusing on dermatology.
• Generate revenue through the sale of ZELSUVMI for the treatment of molluscum contagiosum.
• Utilize the NITRICIL technology platform for the development of new therapies.
• Pursue strategic collaborations and partnerships to expand market reach and product development.

What Industry Does PTHS Operate In?

Pelthos Therapeutics operates within the biotechnology industry, a sector characterized by high innovation, regulatory scrutiny, and capital intensity. The market for dermatological treatments is substantial, driven by increasing awareness and demand for effective therapies. Competition includes established pharmaceutical companies and emerging biotech firms. Pelthos's success depends on its ability to differentiate its products, navigate regulatory pathways, and secure market share in a competitive landscape. The company's NITRICIL technology platform offers a potential competitive advantage in developing novel therapies.

Who Are PTHS's Key Customers?

• Patients with molluscum contagiosum.
• Dermatologists and healthcare providers who prescribe ZELSUVMI.
• Pharmacies and distributors that supply ZELSUVMI.
• Potential partners in the pharmaceutical and biotechnology industries.

Pelthos Therapeutics Inc. (PTHS) Valuation Context

Valued at $78.0M, PTHS is classified as a micro-cap stock. Analyst price targets span from $45.00 to $64.00, with a consensus of $54.50. At the current price of $22.43, that implies approximately 143% upside potential. Relative to its peer group, PTHS's quantitative score of 18/100 is below the peer average of 77/100.

PTHS Revenue & Earnings Trend

In Q2 FY2026, PTHS generated $15.6M in top-line revenue, marking a sequential increase of 43.1%. The company recorded a net loss of $23.4M, with diluted EPS of $-6.62. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, PTHS averaged $-10.48 in diluted EPS.

Company Profile

Pelthos Therapeutics Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Durham, US. The company is led by CEO Scott Plesha. PTHS has traded publicly since 2024.

Key Financial Metrics

Return on assets is -35.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -35.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.76 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -53.9%, the inverse of the P/E and a quick read on earnings relative to price.

Pelthos Therapeutics Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -1.84 places it in the distress zone, a signal of elevated financial risk.

Pelthos Therapeutics Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 114.7% below estimates on average.

Over the past six months, Pelthos Therapeutics Inc. insiders filed 23 SEC Form 4 transactions — 20 sales and 3 purchases. On net that is roughly 32K shares acquired (about $1.1M) — insiders putting money in tends to read as conviction.

PTHS Financials

PTHS Latest News

PTHS Analyst Consensus

PTHS MoonshotScore

What Investors Ask About Pelthos Therapeutics Inc. (PTHS) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources